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technical support and building capacity among health-
care professionals in various southeast Asian countries.8 
The World Stroke Organization global stroke action 
plan9 acknowledges the need to consider the diversity of 
stroke care systems across the world, and recommends 
setting up context appropriate and realistic priorities 
and goals.  
Many evidence-based guidelines exist, but they have 
mostly been based on data gathered in high-resource 
settings and their implementation into clinical practice 
in low-resource settings carries many challenges. 
Region-specific adaptations of guidelines and their 
incorporation into clinical practice to guide national 
stroke care is essential to bridge the gaps in stroke care 
between high-income countries and low-income and 
middle-income countries. The Angels Initiative has been 
influential in implementing global quality campaigns for 
improvement of stroke services across many countries.10 
Stroke is a preventable, treatable, and manageable 
disease. The challenge is to discern which fundamental 
elements across the continuum of stroke care can 
be improved cost-effectively to maximise benefit. 
Implementing an integrated approach towards evidence-
driven policy making, with active collaboration with the 
health-care policy makers, stakeholders, and government 
agencies, is the path to diminishing the inequalities in 
stroke prevention and care across the world.
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Levosimendan for amyotrophic lateral sclerosis
Muscle weakness is the main characteristic of 
amyotrophic lateral sclerosis, which eventually leads 
to functional impairment and respiratory insufficiency. 
Progressive weakness derives from a loss of motor units 
and active muscle fibres. Striated muscle contraction 
depends on the interaction between intracellular 
calcium and the protein troponin. Troponin is made up 
of three subunits—troponin C is especially important 
for binding calcium and promoting a dynamic interplay 
between troponin and tropomyosin, with consequent 
muscle contraction.1 It has been suggested that a 
drug able to increase the affinity of troponin C to 
calcium (a calcium sensitiser) would stimulate stronger 
contractions.2 In patients with amyotrophic lateral 
sclerosis, a stronger contraction of surviving muscle 
fibres might compensate the weakness originating from 
the reduced number of motor units.
Levosimendan is a drug developed and approved 
in the EU to treat severe heart failure by intravenous 
administration. Its principal pharmacological 
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effect is to increase cardiac contractility by calcium 
sensitisation of troponin C. Because of the positive 
action of the drug on the neuromechanical efficiency 
and contractile function of the diaphragm in healthy 
controls, levosimendan was considered potentially 
useful for treating amyotrophic lateral sclerosis, a 
disease characterised by progressive upper and lower 
motor neuron deficits.3 This hypothesis was tested in 
the phase 2 LEVALS trial,4 in which the drug was given 
orally. The primary endpoint of that trial was not met, 
but in a post-hoc analysis, a positive effect on supine 
slow vital capacity (SVC) was found at 12 weeks. In 
another trial5 of a different drug (tiramsentiv) with a 
similar mechanism of action, the findings were also 
negative as tiramsentiv did not diminish the SVC rate 
of decay in the treatment group.5
In The Lancet Neurology, Merit Cudkowicz and 
colleagues present findings of the REFALS study, 
which was done at 99 centres across 14 countries, 
in Australia, Europe, and North America.6 In this 
randomised trial, a large cohort of patients with 
amyotrophic lateral sclerosis received either oral 
levosimendan (n=329) or placebo (n=167) over 
a 48-week period. The primary endpoint was 
change in supine SVC at 12 weeks from baseline 
(estimated treatment difference 0·26%, 95% CI 
–2·03 to 2·55, p=0·83), which did not show any effect 
of levosimendan. The key secondary endpoint was 
the combined assessment of function and survival 
(CAFS), incorporating the revised ALS Functional 
Rating Scale (ALSFRS-R), which was assessed at 
48 weeks, also showing no benefit of the study drug 
(least squares mean change from baseline 10·69, 
95% CI –15·74 to 37·12). Despite incorporating a 
testing hierarchy for the primary and secondary 
endpoints, several other secondary endpoints were 
also analysed by the authors at 48 weeks, including 
the ALSFRS-R respiratory subdomain score and 
time to ventilatory support. No prespecified trial 
endpoint showed a benefit of levosimendan versus 
placebo. Detailed analysis of ALSFRS-R in specific 
subgroups indicated some potential positive results 
of levosimendan, but the clinical relevance of these 
findings is dubious.
The rationale for the REFALS study is understandable 
since, although a drug such as levosimendan was not 
expected to cure amyotrophic lateral sclerosis or to halt 
disease progression, a positive effect on the decline of 
respiratory function would be important. Considering 
the trial duration, number of patients recruited, and 
the large number of centres involved, this trial must 
have been expensive and hard to manage. The authors 
were, therefore, assiduous in extracting a large amount 
of information, particularly regarding the extensive 
analysis of patient subgroups.
The decision to assess the primary endpoint at 
12 weeks in the 48-week REFALS study was probably 
influenced by the results of the phase 2 LEVALS trial.4 
In that study, levosimendan was reported to reduce 
the decline in supine SVC within a short period. The 
total duration of LEVALS was 6 months, and the trial 
followed a complex design, consisting of three 14-day 
crossover treatment periods separated by washout 
periods of 19–23 days.4 In their discussion, Cudkowicz 
and colleagues argue that analysing the primary 
endpoint at 12 weeks instead of 48 weeks in REFALS 
could obviate the effect of dropouts and patients on 
ventilatory support later in the trial. However, some 
complementary measurements would have been 
informative, the first of which would be to combine 
changes at 12 weeks with later evaluations of supine 
SVC. A second approach would be to add additional 
respiratory tests to ascertain changes in respiratory 
function not detected by supine SVC, such as nocturnal 
oximetry or capnography, and maximal inspiratory 
pressures. Taking into account the potential effect 
of levosimendan on diaphragm neuromechanical 
properties, adding neurophysiological studies would 
also have been opportune.7 Finally, including a wet 
biomarker,8 in particular blood neurofilaments, would 
have added information on potential correlations with 
respiratory function.
When designing the REFALS study, in their sample 
size calculation, Cudkowicz and colleagues proposed a 
small difference between the study groups as clinically 
significant (3·6%). Considering this small effect, and 
that the trial did not meet any of the prespecified 
endpoints, levosimendan is probably ineffective in 
amyotrophic lateral sclerosis. Muscle cell physiology 
is different in skeletal muscles and the myocardium. 
Although levosimendan had some positive effects 
in the diaphragm of healthy controls, its effect 
on partly denervated skeletal muscle is unknown. 
Therefore, the results of the REFALS study should 
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not necessarily prevent testing of other drugs with 
a similar mechanism of action, such as reldesemtiv 
(NCT04944784). Cudkowicz and colleagues should 
be congratulated on completing this difficult trial and 
for sharing their results. Amyotrophic lateral sclerosis 
researchers should recognise the effort put into and 
lessons taken from this trial, particularly regarding 
the study design. To find an effective drug to treat 
amyotrophic lateral sclerosis is a major challenge, 
and at the core of this challenge are the choice of a 
relevant compound and the use of the best methods 
for measuring treatment outcomes.
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Buying time for infants with spinal muscular atrophy 
Loss-of-function mutation of the survival motor 
neuron 1 (SMN1) gene on chromosome 5q causes 
hereditary proximal spinal muscular atrophy, a 
neuromuscular disorder characterised by severe infantile 
or childhood-onset muscle weakness. Despite the 
disorder being rare, with an incidence of around 1 per 
10000 livebirths, spinal muscular atrophy is one of the 
most common hereditary causes of severe disability. 
5 years ago, infantile-onset spinal muscular atrophy 
type 1 was also the most common genetic cause of 
infantile death;1 since then, prospects for children with 
this disorder have changed because of the stepwise 
introduction of three genetic therapies.2–6 This progress 
was inspired by the discovery that spinal muscular 
atrophy is caused by reduced expression of SMN protein 
due to a homozygous deletion of SMN1, and that the 
copy number of the highly homologous, but dormant, 
gene SMN2 determines most of the clinical variability 
between patients.7 Two of the currently available genetic 
therapies for spinal muscular atrophy (nusinersen and 
risdiplam) modify SMN2 mRNA splicing and thereby 
increase intracellular SMN protein concentrations.2,3 
The approach of the other therapy (onasemnogene 
abeparvovec) is to reintroduce the absent SMN1 gene 
into α motor neurons in the anterior horn of the spinal 
cord. Gene therapy relies on adeno-associated virus 
serotype 9 (AAV9) particles that are loaded with human 
SMN1 and act as vectors.4–6 In The Lancet Neurology, 
Eugenio Mercuri and colleagues6 report results from the 
STR1VE-EU study, in which they assessed the safety and 
efficacy of onasemnogene abeparvovec for infants with 
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